Related Experiment Video

Updated: Apr 14, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.5K

MET receptor is a potential therapeutic target in high grade cervical cancer

Katarzyna Miekus1, Marta Pawlowska2, Małgorzata Sekuła2

  • 1Department of General Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Cracow, Poland.

Oncotarget
|April 19, 2015
PubMed

Insights

Targeting the MET receptor significantly inhibits advanced cervical cancer growth and progression. Silencing MET reduces tumor cell size and proliferation, offering a promising therapeutic strategy for cervical carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cervical cancer remains a significant cause of mortality in women.
  • Existing treatments for advanced cervical cancer have limitations.
  • The MET receptor's role in cervical carcinoma is not well-defined.

Purpose of the Study:

  • To investigate the MET receptor as a potential therapeutic target in advanced cervical cancer.
  • To elucidate the function of the MET receptor in cervical carcinoma cell lines.
  • To assess the impact of MET receptor downregulation on tumor growth and cellular characteristics.

Main Methods:

  • Utilized RNA interference to downregulate MET receptor expression in cervical carcinoma cell lines.
  • Evaluated tumor growth, cell size, and proliferation rates in vitro and in vivo.
  • Assessed the expression levels of key proteins including cyclin D1, c-myc, SLUG, E-cadherin, and CXCR4.

Main Results:

  • MET receptor downregulation significantly reduced tumor growth and induced differentiation in vivo.
  • Silencing MET decreased cell size and proliferation under various conditions.
  • MET downregulation led to reduced cyclin D1 and c-myc, decreased SLUG, increased E-cadherin, and impaired CXCR4 signaling.
  • Apoptosis was not significantly increased by MET receptor downregulation.

Conclusions:

  • The MET receptor plays a crucial role in the oncogenic properties of cervical carcinoma cells.
  • MET receptor downregulation inhibits tumor growth, proliferation, and invasion.
  • The MET receptor represents a potential therapeutic target for advanced cervical cancer.
Keywords:
CXCR4E-cadherinMETcervical cancerdifferentiation

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

10.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K